Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 3/20 | 0.38 |
| ▸ | JAK3 | P52333 | 3/20 | 0.36 |
| ▸ | BTK | Q06187 | 3/20 | 0.36 |
| ▸ | MDM4 | O15151 | 1/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 2/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL984600 | 0.91 | BTK (0.40) | PAK1BTKMDM4MEN1KMT2A | |
| SCHEMBL986013 | 0.89 | MEN1 (0.46) | MEN1KMT2AKDM4EALDH1A1HSD17B10 | |
| SCHEMBL983264 | 0.88 | BTK (0.40) | PAK1BTKMEN1KMT2AALDH1A1 | |
| SCHEMBL985290 | 0.88 | KDM5A (0.37) | PAK1BTKMDM4KMT2AHTR7 | |
| SCHEMBL985879 | 0.88 | MTNR1B (0.40) | PAK1JAK3MDM4CYP4F2CYP4A11 | |
| SCHEMBL981830 | 0.88 | MTNR1B (0.40) | PAK1JAK3KMT2ACYP4F2CYP4A11 | |
| SCHEMBL983123 | 0.88 | PARP1 (0.45) | BTKMEN1KMT2AALDH1A1 | |
| SCHEMBL983559 | 0.87 | PTK2 (0.39) | MEN1KMT2AALDH1A1 | |
| SCHEMBL984599 | 0.86 | BTK (0.39) | BTK | |
| SCHEMBL982008 | 0.86 | BTK (0.40) | BTKKMT2ACYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | claimed |
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | PDE5A, PDE3A, PDE2A | PAK1 1999/4885JAK3 1732/4885BTK 1977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.